Protective Effect of Mannitol on Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-Analysis

Li, Songtao; He, Xiuyun; Ruan, Linjie; Ye, Ting; Wen, Yulong; Song, Zhihua; Hu, Siying; Chen, Yu; Peng, Bo; Li, Shijie

doi:10.3389/fonc.2021.804685

Cited by 17 publications

(6 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mannitol was an effective and safe drug to reduce cisplatin‐induced nephrotoxicity events, which had a better effect on gastrointestinal and urinary tract cancers 31 . Maltitol is a disaccharide alcohol that is produced by hydrogenation of maltose, and stimulated transepithelial diffusional calcium transfer in the ileum 32 .…”

Section: Discussionmentioning

confidence: 99%

“…30 Mannitol was an effective and safe drug to reduce cisplatin-induced nephrotoxicity events, which had a better effect on gastrointestinal and urinary tract cancers. 31 Maltitol is a disaccharide alcohol that is produced by hydrogenation of maltose, and stimulated transepithelial diffusional calcium transfer in the ileum. 32 Linoleic acid derivative 13(S)-hydroxyoctadecadienoic acid (13(S)-HODE) was concomitant with increased NF-κB activity, 33 and was closely related to non-small-cell lung cancer, 34 breast cancer, 35 and colon cancers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Potential serum metabolites and long‐chain noncoding RNA biomarkers for endometrial cancer tissue

Hao

Lin

Liu

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Background Endometrial carcinoma (EC) is one of the most common tumors in the female reproductive system. There are nearly 200 000 new cases every year. It is the third most common gynecological malignant tumor leading to female death. The incidence rate is closely related to lifestyle, and the incidence rate varies in different regions. The incidence rate of EC is ranking the first in the female reproductive system cancer just second only to breast, lung, and colorectal cancer in North America and Europe and the incidence rate of EC is only second, followed by breast cancer and cervical cancer in China. Purpose The potential metabolic markers of endometrial cancer were screened by liquid chromatograph mass spectrometer (LC‐MS), and the tissues of patients with hysteromyoma and endometrial cancer were sequenced to explore the relationship between the disease and change in the content of long‐chain noncoding RNA (lncRNA). Methods Serum and tissue samples were collected from patients with endometrial dysplasia, endometrial cancer stage I, and endometrial cancer stage III. The metabolites in all serum samples were extracted, and the metabolites in all samples were detected by LC–MS/MS technology. The Pareto‐scaling method was used for normalization, and the MetaboAnalyst 4.0 software was used for different analyses. The T test between groups showed that p ≤ 0.05 was regarded as the metabolite with a difference. Further, the function of differential metabolites was determined by metabolite function enrichment and co‐expression analysis. Meanwhile, the differentially expressed lncRNA was detected by Illumina second‐generation high‐throughput sequencing technology, and the expression was analyzed by DEGseq software. Different lncRNA were screened according to p < 0.05. LncRNA with significant differences were screened by p < 0.01, q < 0.001, fold change ≥2, and false discovery rate (FDR) ≤0.001. Results Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3‐Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)‐HODE (AUC = 0.88), and D‐Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III. At the same time, lncRNA sequencing results showed that when endometrial atypical hyperplasia continued to change, including LINC00511, PVT1, and IQCH‐AS1 (downregulated), and only changed significantly in the endometrial dysplasia group, including MALAT1, CARMN (downregulated) and LINC00648, BISPR, LINC01534, and LINC00930 (upregulated). Moreover, both differential metabolites and differential lncRNA were annotated to the lipid metabolism pathway, suggesting that this pathway played an important role in the occurrence and development of endometrial carcinoma. Conclusions It can combine the results of metabolomics and lncRNA sequencing to assist in the early diagnosis of endometrial precancerous lesions and endomet...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Potential serum metabolites and long‐chain noncoding RNA biomarkers for endometrial cancer tissue

Hao

Lin

Liu

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Li et al [ 38 ] recently published the results of a meta-analysis of four randomized control trials and seven case-control studies involving 4,168 patients. The results indicated that mannitol causes more nausea/vomiting events and deteriorates renal function in patients with diabetes or hypertension; however, it had the best effect when ≥25 g in total or cisplatin <75 mg/m 2 was administered and might have a better effect on gastrointestinal and urinary tract cancers.…”

Section: Discussion/conclusionmentioning

confidence: 99%

A Randomized Phase 2 Study of 5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate for the Prevention of Nephrotoxicity Induced by Cisplatin-Based Chemotherapy of Lung Cancer

Kawamura¹,

Matsushima²,

Iwashima³

et al. 2022

Oncology

View full text Add to dashboard Cite

Introduction: Cisplatin-based chemotherapy was established in the 1980s, and it has been improved by the development of a short hydration protocol in lung cancer therapy. However, cisplatin-based chemotherapy is still associated with renal toxicity. Because 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) is known to be a mitochondrial activator and a heme oxygenase-1 (HO-1) inducer, 5-ALA with SFC is speculated to mitigate cisplatin-induced renal inflammation. Methods: We investigated the effects of oral administration of 5-ALA with SFC for preventing cisplatin-based nephrotoxicity in patients with lung cancer and evaluated its benefits for patients who received cisplatin-based chemotherapy. The primary endpoint was the significance of the difference between the serum creatinine (sCr) levels of the patients administered 5-ALA with SFC and those given placebo after course 1 of chemotherapy. The difference in the estimated glomerular filtration rate (eGFR) between the two groups was also evaluated as the secondary endpoint. Results: The double-blind, randomized two-arm studies were conducted at 15 medical facilities in Japan; 54 male and 20 female patients with lung cancer who received cisplatin-based chemotherapy between the ages of 42 and 75 were included in the study. The compliance rate was greater than 94% in the primary assessment and subsequent drug administration periods. All enrolled patients completed the four cycles of cisplatin-based chemotherapy with short hydration. The average level of sCr on day 22 of course 1 was 0.707 mg/dL in the group treated with 5-ALA and SFC and 0.735 mg/dL in the placebo group, respectively, and the sCr in the test group was significantly lower than that in the placebo group (P = 0.038). In addition, the eGFR was significantly higher in the SPP-003 group than in the placebo group up to day 1 of course 3 (84.66 and 75.68 mL/min, respectively, P = 0.02) and kept better even after the last administration of the study drug (82.37 and 73.49 mL/min, respectively, P = 0.013). Conclusions: The oral administration of 5-ALA with SFC is beneficial to patients undergoing cisplatin-based chemotherapy for lung cancer with short hydration.

show abstract

“…To further test the potential protective properties of FeS preconditioning, its ability to mitigate cisplatin nephrotoxicity was assessed. Given that significant nephrotoxicity occurs in ~30% of cisplatin‐treated patients (Li et al, 2021 ), FeS mediated renal preconditioning could find substantial clinical application. As shown in the bottom panels of Figure 3 , within 3 days of cisplatin (CP) injection, severe AKI was observed in non‐preconditioned mice (Zager et al, 2021 ).…”

Section: Iron Sucrose: a Trigger For Oxidant Preconditioning And Indu...mentioning

confidence: 99%

Oxidant‐ induced preconditioning: A pharmacologic approach for triggering renal ‘self defense’

Zager

2022

Physiological Reports

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a common event, occurring in ~5% and ~35% of hospitalized and ICU patients, respectively. The development of AKI portends an increased risk of morbidity, mortality, prolonged hospitalization, and subsequent development of chronic kidney disease (CKD). Given these facts, a multitude of experimental studies have addressed potential methods for inducing AKI prevention in high‐risk patients. However, successful clinical translation of promising experimental data has remained elusive. Over the past decade, our laboratory has focused on developing a method for safely triggering AKI protection by inducing “kidney preconditioning” in mice by the intravenous administration of a combination of Fe sucrose (FeS) + tin protoporphyrin (SnPP). These agents induce mild, but short lived, ‘oxidant stress’ which synergistically activate a number of kidney ‘self‐defense’ pathways (e.g., Nrf2, ferritin, IL‐10). Within 18–24 h of Fe/SnPP administration, marked protection against diverse forms of experimental toxic and ischemic AKI results. FeS/SnPP‐mediated reductions in kidney injury can also indirectly decrease injury in other organs by mitigating the so called “organ cross talk” phenomenon. Given these promising experimental data, three phase 1b clinical trials were undertaken in healthy subjects and patients with stage 3 or 4 CKD. These studies demonstrated that FeS/SnPP were well tolerated and that they up‐regulated the cytoprotective Nrf2, ferritin, and IL‐10 pathways. Two subsequent phase 2 trials, conducted in patients undergoing ‘on‐pump’ cardiovascular surgery or in patients hospitalized with COVID 19, confirmed FeS/SnPP safety. Furthermore, interim data analyses revealed statistically significant improvements in several clinical parameters. The goals of this review are to: (i) briefly discuss the historical background of renal “preconditioning”; (ii) present the experimental data that support the concept of FeS/SnPP‐ induced organ protection; and (iii) discuss the initial results of clinical trials that suggest the potential clinical utility of an ‘oxidant preconditioning’ strategy.

show abstract

Protective Effect of Mannitol on Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-Analysis

Cited by 17 publications

References 81 publications

Potential serum metabolites and long‐chain noncoding RNA biomarkers for endometrial cancer tissue

Potential serum metabolites and long‐chain noncoding RNA biomarkers for endometrial cancer tissue

A Randomized Phase 2 Study of 5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate for the Prevention of Nephrotoxicity Induced by Cisplatin-Based Chemotherapy of Lung Cancer

Oxidant‐ induced preconditioning: A pharmacologic approach for triggering renal ‘self defense’

Contact Info

Product

Resources

About